Bile acid conjugates for improving the oral bioavailability of bisphosphonates

Award Information
Agency:
Department of Health and Human Services
Amount:
$255,852.00
Program:
SBIR
Contract:
1R43AR055402-01A1
Solitcitation Year:
2008
Solicitation Number:
PHS2007-2
Branch:
N/A
Award Year:
2008
Phase:
Phase I
Agency Tracking Number:
AR055402
Solicitation Topic Code:
N/A
Small Business Information
TSRL, INC.
TSRL, INC., 540 AVIS DR, STE A, ANN ARBOR, MI, 48108
Hubzone Owned:
Y
Woman Owned:
Y
Socially and Economically Disadvantaged:
Y
Duns:
156551699
Principal Investigator
 () -
Business Contact
Phone: (734) 663-4233
Email: jhilfinger@tsrlinc.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Bisphosphonates are chemically and enzymatically stable analogues of inorganic pyrophosphate that interfere with specific biochemical and enzymatic pathways of the bone-resorbing osteoclasts. The development of the bisp hosphonates has yielded effective treatments for various diseases of excessive bone resorption, including Paget's disease of bone, myeloma, bone metastases, and osteoporosis. However, the bisphosphonates are associated with two major problems, poor oral bi oavailability (lt1% in humans) and a high rate of gastrointestinal mucosal damage that limit effectiveness and long-term tolerability. At TSRL, we have created carrier molecules, termed Bile Acid Conjugates (BAC) that enhance the oral bioavailability of po orly absorbed, charged molecules. The goal of the current project is to use the BAC technology to improve the oral bioavailability of alendronate, the leading bisphosphonate on the market (Fosamax). We hypothesize that the BAtify the efficacy of this thera py in an ovarectomized rodent model. This collaboration will allow us to systematically test the effect of a diverse library of BAC carrier molecules on alendronate transport, oral bioavailability, and efficacy in an animal model. Public Health Rele vance: This project specifically involves the development of a new drug carrier to enhance oral absorption for poorly absorbed drugs like alendronate and other bisphosphonates currently used for the treatment of osteoporosis.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government